XBiotech Inc (4XB F) stock market data APIs
€2.5642
0(0%)
as of July 4, 2025
Try our APIs with
free plan!
XBiotech Inc Financial Data Overview
Price chart is built with
Anychart
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Prev. Close
2.5642
Open
2.5642
High
2.5642
Low
2.5642
52 wk Range
2-7.55
Market Cap
80 888 K
Shares Outstanding
30 488 K
Revenue
300 K
EPS
0
Beta
0.966
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get XBiotech Inc data using free add-ons & libraries
Get XBiotech Inc Fundamental Data
XBiotech Inc Fundamental data includes:
- Net Revenue: 300 K
- EBITDA: -43 413 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2020-03-31
- EPS/Forecast: 0.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
XBiotech Inc News
New
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
XBiotech Inc. XBiotech Architectural Rendition of XBiotech’s Planned R&D Facility XBiotech Architectural Rendition of XBiotech’s Planned R&D Facility AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIR...
Companies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new trea...
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
XBiotech Inc. (Phase II Multicenter Study is Proceeding Well with High Anticipation) AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) today announced that Alan Kivitz M.D. is...
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
XBiotech Inc. AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
